{'fraction_non_alphanumeric': 0.02945736434108527, 'fraction_numerical': 0.01937984496124031, 'mean_word_length': 4.637554585152839, 'pattern_counts': {'":': 0, '<': 1, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
DETERMINE THE EFFICACY AND SAFETY OF BETAHISTINE IN TREATING VERTIGO AMONG PATIENTS AT TERTIARY CARE HOSPITAL.

Aim:  to determine the efficacy and safety of betahistine in treating vertigo among patients at tertiary care hospital. 
Materials and Methods: the present open label interventional study was conducted on 50 patients of confirmed peripheral vertigo visited the department of ENT, Nalanda Medical College and Hospital, Patna, Bihar, India. Patients received 48mg betahistine (16mg, TDS) for 21 days, and were followed up on day 0, 7 and 21. Safety and effectiveness were assessed based on clinical response (scale for vestibular vertigo severity level and clinical response evaluation (SVVSLCRE). 
Results: mean age of the study population was 42.16 years and majority of them were females. Betahistine was found to be effective at 16mg TDS, given up to 21days, by   demonstrating   a   significant   reduction   in   vertigo severity    (p<0.0001),    as    assessed    by    changes in score of vestibular vertigo severity level and clinical response evaluation (SVVSLCRE) level. 
Conclusions: Betahistine was found to be effective in controlling vertigo and easily tolerated in the study population with no major adverse effect. 
Keywords: Betahistine, Vertigo, Saftey, Nausea